

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2016 OS WB

DISPATCHED ON 26TH JULY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A24; B35, B49; Cw7, Cw9; DR4, DR13; DQ6, DQ7

		Summary of Results									
		PBL/T-Cells				B-Cells					
Total tested		18	18	18	16	13	14	12	13		
Positive		0	16	0	4	0	14	0	9		
Negative		18	2	18	12	13	0	12	4		
NT/Equivocal		0	0	0	2	2	1	3	2		
% Positive		0.0%	88.9%	0.0%	25.0%	0.0%	100.0%	0.0%	69.2%		
% Negative		100.0%	11.1%	100.0%	75.0%	100.0%	0.0%	100.0%	30.8%		
Consensus		Negative	Positive	Negative	Negative	Negative	Positive	Negative	Not Assessed		
HLA Antibody Specificity (Defined By CDC)		A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1		
		Without DTT				Without DTT					
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
101	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Viability of B cells does not meet the criteria for the test
114	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
116	YES	YES	Negative	Positive	Negative	Positive	NT	NT	NT	NT	
117	YES	NO	Negative	Positive	Negative	Equivocal					
136	YES	NO	Negative	Positive	Negative	Positive					
145	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
149	YES	NO	Negative	Positive	Negative	Equivocal					
162	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
163	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
186	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
204	YES	YES	Negative	Positive	Negative	Negative	Equivocal	Positive	Equivocal	Positive	
206	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
212	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
227	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	NT	NT	
268	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
284	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
311	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
315	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2016 OS WB

DISPATCHED ON 26TH JULY 2016

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101	1	6	1	1	1	8	1	4			
114	1	4	1	1	1	8	1	1			
116	1	2-4	1	1-2	NT	NT	NT	NT	93	95	50
117	1	4	1								
136	1	6	1	4						95	
145		4-6		2-4		8		8		100	100
149		4-6							80		
162		4/6				8		8		100	100
163	1	6	1	1	1	8	1	8		90	90
186	0	4	0	0	0	8	0	4		99	99
204	1	4	1	1	4	8	4	6		90	85
206	1	4	1	2	1	8	2	6		100	100
212									99	99	99
227		6				8	NT	NT	90	90	90
268	1	4	1	1	1	6	1	1		96	96
284	1	6	1	4	1	8	1	8		99	90
311	1	6	1	1	1	8	1	8		95	95
315	1	1	1	1	1	8	1	1		80	80

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2016 OS WB

DISPATCHED ON 26TH JULY 2016

Lab No.	Summary of Results															
	PBL				PBL Without DTT				T-Cells				T-Cells Without DTT			
	Without DTT				Serum 1	Serum 2	Serum 3	Serum 4	Without DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
114	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Negative	1	4	1	1
117	Negative	Positive	Negative	Equivocal	1	4	1	-	NT	NT	NT	NT	NT	NT	NT	NT
145	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Positive	-	-	-	-
162	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Negative	-	4/6	-	-
227	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Negative	-	6	-	-
284	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Positive	1	6	1	4

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2016 OS WB

DISPATCHED ON 26TH JULY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A24; B35, B49; Cw7, Cw9; DR4, DR13; DQ6, DQ7

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested	15	15	15	14	12	13	11	12			
Positive	0	12	0	1	0	13	0	0			
Negative	15	3	15	13	12	0	11	12			
NT/Equivocal	0	0	0	1	2	1	3	2			
% Positive	0.0%	80.0%	0.0%	7.1%	0.0%	100.0%	0.0%	0.0%			
% Negative	100.0%	20.0%	100.0%	92.9%	100.0%	0.0%	100.0%	100.0%			
Consensus	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative			
HLA Antibody Specificity (Defined By CDC)	A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1			
Lab No.	PBL/T Cell Assessment	B Cell Assessment	With DTT				With DTT				Comments
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
101	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Viability of B cells does not meet the criteria for the test
114	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
116	YES	YES	Negative	Positive	Negative	Positive	NT	NT	NT	NT	
149	YES	NO	Negative	Positive	Negative	Equivocal					
162	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
163	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
186	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
204	YES	YES	Negative	Positive	Negative	Negative	Equivocal	Positive	Equivocal	Negative	
206	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
212	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
227	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	NT	NT	
268	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
284	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
311	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
315	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
											Technical failure on Serum 3 and 4, B-cells

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2016 OS WB

DISPATCHED ON 26TH JULY 2016

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101	1	4	1	1	1	8	1	1			
114	1	4	1	1	1	8	1	1			
116	1	4	1	1-2	NT	NT	NT	NT		95	50
149		4							80		
162		4				8				100	100
163	1	6	1	1	1	8	1	1		90	90
186	0	4	0	0	0	8	0	0		99	99
204	1	4	1	1	4	8	4	4		90	85
206	1	1	1	1	1	8	2	1		100	100
212									99	99	99
227		6				8	NT	NT	90	90	90
268	1	4	1	1	1	6	1	1		96	96
284	1	8	1	1	1	8	1	1		99	90
311	1	6	1	1	1	8	1	1		95	95
315	1	1	1	1	1	8	1	1		80	80

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2016 OS WB

DISPATCHED ON 26TH JULY 2016

Lab No.	Summary of Results															
	PBL				PBL With DTT				T-Cells				T-Cells With DTT			
	With DTT				Serum 1	Serum 2	Serum 3	Serum 4	With DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
114	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Negative	1	4	1	1
117	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
145	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
162	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Negative	-	4	-	-
227	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Negative	-	6	-	-
284	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Negative	1	8	1	1